There are currently no events to display.

Recent News

Date Title and Summary
Toggle Summary ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors
New Directors Bring Extensive Medical Device Experience to the Board CLEVELAND , Feb. 7, 2018 /PRNewswire/ -- ViewRay, Inc. (Nasdaq: VRAY), maker of the world's first and only clinical MRI-guided radiation therapy system, announced today the appointment of medical device industry veterans Scott
Toggle Summary ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results
CLEVELAND , Jan. 8, 2018 /PRNewswire/ --  ViewRay, Inc. (Nasdaq: VRAY) today announced preliminary results for the fourth quarter and full fiscal year ended December 31, 2017 . The preliminary results reported have not been audited and are subject to change.
Toggle Summary Oncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation Therapy
Educational Event Aimed at Sharing Clinical Knowledge and Best Practices for Establishing an MR Image-guided Radiation Therapy Program CLEVELAND , Dec. 19, 2017 /PRNewswire/ -- Experts in MR image-guided radiation therapy will share their experiences during a global symposium to be held on Friday,
Toggle Summary ViewRay® to Participate in Upcoming Conferences
CLEVELAND , Nov. 21, 2017 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) announced today that Chris Raanes , Chief Executive Officer, and Ajay Bansal , Chief Financial Officer are scheduled to participate in two upcoming investor conferences. The first conference is the 29th Annual Piper Jaffray

Corporate Profile

ViewRay® Inc., (NASDAQ:VRAY), designs, manufactures and markets MRIdian® the world’s first and only MRI-guided radiation therapy system that can image and treat cancer patients simultaneously. MRIdian® addresses key limitations of existing external-beam radiation therapy technologies because it integrates MRI technology, radiation delivery and proprietary software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. Real-time MRI-imaging clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment allowing the system to deliver radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian®’s increased target accuracy combined with improved tumor visibility and accurate dose recording means clinicians can treat patients who would not previously have been considered radiation therapy candidates. ViewRay believes MRIdian® will significantly improve the safety and efficacy of radiation therapy, leading to improved patient outcomes with reduced side-effects from off-target radiation delivery.

Featured Items

Upcoming Events

There are currently no events to display.

Stock Quote

Event Calendar more >

Alerts are e-mailed to you whenever certain new company information is posted to this site. Sign-up Now!

Click here for E-mail Alerts

Copyright Nasdaq. Minimum 15 minutes delayed.

Copyright 2018 © ViewRay. All rights reserved